Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: Integrated GWRS and GWGS analyses

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 11, 2014, Pages 4038-4050

  Zhou, Xu ^a   Zhu, Hua Qiang ^a   Lu, Jun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Transcription factor

Indexed keywords

CXCL14 CHEMOKINE; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CXCL14 GENE; FCN2 GENE; GENE; GENE EXPRESSION; GENE ONTOLOGY; GENETIC REGULATION; GENOME ANALYSIS; GENOME WIDE GLOBAL SIGNIFICANCE; GENOME WIDE RELATIVE SIGNIFICANCE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MATHEMATICAL GENETICS; MICROARRAY ANALYSIS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84918567175     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Chuang SC, Vecchia CL, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 2009; 286: 9-14.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34: S1-S3.
4. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-495.
5. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clinl Invest 2009; 119: 1745-1754.
6. Javadi A, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health 2006; 35: 33-36.
7. Young EJ. Brucella species. In: Mandell G, Bennett JE, Dolin R, editors. Mandell G, Douglas and Bennett’s principles and practice of infectious diseases. 6th edition. Philadelphia, USA: Elsevier Churchill Livingstone; 2005. pp. 2669-74.
8. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
9. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepatitis 2009; 16: 265-271.
10. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
11. Jin Y, Yun C, Park C, Wang HJ, Cho H. Expression of hepatitis B virus X protein is closely correlated with the high periportal inflammatory activity of liver diseases. J Viral Hepatitis 2001; 8: 322-330.
12. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H, Kim DK, Yu DY, Seong JK, Lee MO. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1a through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076-39084.
13. Sanz-Cameno P, Martín-Vílchez S, Lara-Pezzi E, Borque MJ, Salmerón J, Muñoz de Rueda P, Solís JA, López-Cabrera M, Moreno-Otero R. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006; 169: 1215-1222.
14. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991; 252: 842-844.
15. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. P Natl Acad Sci U S A 2009; 106: 19975-19979.
16. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008; 38: 1-26.
17. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135.
18. Abe M, Koga H, Yoshida T, Masuda H, Iwamoto H, Sakata M, Hanada S, Nakamura T, Taniguchi E, Kawaguchi T. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-?B/hypoxia-inducible factor-1a axis under hypoxic conditions. Hepatol Res 2012; 42: 591-600.
19. Benegiamo G, Vinciguerra M, Mazzoccoli G, Piepoli A, Andriulli A, Pazienza V. DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Digest Dis Sci 2012; 57: 1598-1603.
20. Toyota M, Suzuki H. Epigenetic drivers of genetic alterations. Adv Genet 2010; 70: 309-323.
21. Lim JS, Park SH, Jang KL. Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Lett 2012; 321: 154-161.
22. Lee H, Woo YJ, Kim SS, Kim SH, Park BJ, Choi D, Jang KL. Hepatitis C virus Core protein overcomes all- trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-ß2 expression via DNA methylation. Cancer Lett 2013; 335: 372-379.
23. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010; 70: 10202-10212.
24. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One 2013; 8: e59459.
25. Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H, Kaneda A. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2010; 101: 1501-1510.
26. Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res 2013; 19: 1827-1837.
27. Jurman G, Merler S, Barla A, Paoli S, Galea A, Furlanello C. Algebraic stability indicators for ranked lists in molecular profiling. Bioinformatics 2008; 24: 258-264.
28. Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis. Peer J 2013; 1: e49.
29. Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. pp. 397-420.
30. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
31. Consortium GO. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004; 32: D258-D261.
32. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
33. Dawson JA, Ye S, Kendziorski C. R/EBcoexpress: an empirical Bayesian framework for discovering differential co-expression. Bioinformatics 2012; 28: 1939-1940.
34. Dawson JA, Kendziorski C. An empirical bayesian approach for identifying differential coexpression in high-throughput experiments. Biometrics 2012; 68: 455-465.
35. Ma C, Lv Q, Cao Y, Wang Q, Zhou X, Ye B, Yi C. Genes relevant with osteoarthritis by comparison gene expression profiles of synovial membrane of osteoarthritis patients at different stages. Eur Rev Med Pharmacol Sci 2014; 18: 431-439.
36. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet 2009; 10: 252-263.
37. Scardoni G, Laudanna C. Centralities based analysis of complex networks. New Frontiers in Graph Theory. In Tech Open 2012.
38. de Messias-Reason I, Kremsner PG, Kun JF. Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy. J Infect Dis 2009; 199: 801-804.
39. Chen X, Katoh Y, Nakamura K, Oyama N, Kaneko F, Endo Y, Fujita T, Nishida T, Mizuki N. Single nucleotide polymorphisms of Ficolin 2 gene in Behçet’s disease. J Dermatol Sci 2006; 43: 201-205.
40. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 1998; 273: 20721-20727.
41. Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet 2005; 14: 1651-1658.
42. Hummelshoj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. Molecular organization of human Ficolin-2. Mol Immunol 2007; 44: 401-411.
43. Luz PR, Boldt AB, Grisbach C, Kun JF, Velavan T., Messias-Reason IJ. Association of L-ficolin levels and FCN2 genotypes with chronic chagas disease. PLoS One 2013; 8: e60237.
44. Tong HV, Toan NL, Song LH, Ouf EA, Bock CT, Kremsner PG, Kun JF, Velavan T. Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One 2011; 6: e28113.
45. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 2004; 64: 8262-8270.
46. Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese NA, Büchler MW, Friess H. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 2008; 259: 209-217.
47. Barbaria EM, Kohl B, Buhren BA, Hasenpusch-Theil K, Kruse F, Küry P, Martini R, Müller HW. The a-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells. Neurobiol Dis 2009; 33: 448-458.
48. Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, Zhou X, Xie H, Zhou L, Zheng S. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci 2013; 104: 1523-1531.
49. Gu X, Wang H, Wang A, Dou T, Qi P, Ji Q, Li H, Gao C. An intronic polymorphism rs2237062 in the CXCL14 gene influences HBV-related HCC progression in Chinese population. Mol Biol Rep 2012; 39: 797-803.
50. Scholl T, Mahanta SK, Strominger JL. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci U S A 1997; 94: 6330-6334.
51. Panchal S, Madan A, Hosur R. Cloning, expression and purification of the DNA binding domain of RFX protein. Indian J Biochem Bio 1999; 36: 429-432.
52. Bonnafe E, Touka M, AitLounis A, Baas D, Barras E, Ucla C, Moreau A, Flamant F, Dubruille R, Couble P. The transcription factor RFX3 directs nodal cilium development and left-right asymmetry specification. Mol Cell Biol 2004; 24: 4417-4427.
53. Bradley JA, Bolton EM, Pedersen RA. Stem cell medicine encounters the immune system. Nat Rev Immunol 2002; 2: 859-871.
54. Hao H, Aixia Y, Nancai Y, Wen S. Baicalin suppresses expression of Chlamydia protease-like activity factor in Hep-2 cells infected by Chlamydia trachomatis. Fitoterapia 2009; 80: 448-452.
55. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, Suzuki H, Sasaki Y, Kanaseki T, Takamura Y. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-?-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 2004; 23: 8876-8886.
56. Scanlan MJ, Gordon CM, Williamson B, Lee SY, Chen YT, Stockert E, Jungbluth A, Ritter G, Jäger D, Jäger E, Knuth A, Old LJ. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002; 98: 485-492.
57. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, Van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
58. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005; 310: 306-310.
59. Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT, Tarakhovsky A. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003; 4: 124-131.
60. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R, Otte AP. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Brit J Haematol 2001; 112: 950-958.
61. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
62. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11611.
63. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, Hotfilder M, Löwel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Müller-Tidow C, Burdach S. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009; 106: 5324-5329.
64. Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
65. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K, Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Brit J Cancer 2005; 92: 1754-1758.
66. Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ. EZH2-mediated concordant repression of Wnt antagonists promotes ß-catenin-dependent hepatocarcinogenesis. Cancer Res 2011; 71: 4028-4039.
67. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2012; 130: 2557-2567.
68. Wu K, Yang Y, Wang C, Davoli MA, D’Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG. DACH1 inhibits transforming growth factor-ß signaling through binding Smad4. J Biol Chem 2003; 278: 51673-51684.
69. Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, Di Vizio D, Wang C, Lisanti MP, Sauter G, Russell RG, Cvekl A, Pestell RG. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 2006; 26: 7116-7129.
70. Zhai Y, Zhou G, Deng G, Xie W, Dong X, Zhang X, Yu L, Yang H, Yuan X, Zhang H, Zhi L, Yao Z, Shen Y, Qiang B, He F. Estrogen receptor a polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006; 130: 2001-2009.
71. Sun M, Mo W, Fu X, Wu G, Huang Y, Tang R, Guo Y, Qiu M, Zhao F, Li L, Huang S, Mao Y, Li Y, Xie Y. System biology analysis of cell cycle pathway involved in hepatocellular carcinoma. Front Biosci (Schol Ed) 2009; 2: 1127-1144.
72. Sun M, Wu G, Li Y, Fu X, Huang Y, Tang R, Guo Y, Qiu M, Mao Y, Zhao F, Li L, Huang S, Zhao X, Xie Y. Expression profile reveals novel prognostic biomarkers in hepatocellular carcinoma. Front Biosci (Elite Ed) 2009; 2: 829-840.
73. Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Proliferat 2011; 44: 291-299.
74. Wenjian J, Kunhe Z, Huoguo C, Qingfeng L. Expression and clinical significance of EphA2 in hepatocellular carcinoma. Chongqing Med 2013; 20: 021.
75. Weng L, Du J, He W, Ling C. Characteristic genomics of peripheral blood mononuclear cells of hepatocellular carcinoma patients with liver-kidney yin deficiency syndrome. J Chin Integ Med 2012; 10: 406-415.
76. Wang SM, Ooi LLP, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011; 17: 6040-6051.
77. Ohh M. pVHL’s kryptonite: E2-EPF UCP. Cancer Cell 2006; 10: 95-97.
78. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006; 25: 4831-4839.
79. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T. Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 2007; 98: 174-181.
80. Lee SW, Reimer CL, Fang L, Iruela-Arispe ML, Aaronson SA. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol 2000; 20: 1723-1732.
81. Zhai Y, Zhou G, Deng G, Xie W, Dong X, Zhang X, Yu L, Yang H, Yuan X, Zhang H, Zhi L, Yao Z, Shen Y, Qiang B, He F. Estrogen receptor a polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006; 130: 2001-2009.
82. Li B, Li XF, Zhou CC. Relationship between DNA repair gene MMS19 single nucleotide polymorphisms and histology of non-small cell lung cancer. Tumor 2011; 31: 751-755.
83. Martin ST, Sato N, Dhara S, Chang R, Hustinx SR, Abe T, Maitra A, Goggins M. Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Bio Ther 2005; 4: 728-733.
84. Wu Y, Guo X, Brandt Y, Hathaway HJ, Hartley RS. Three-dimensional collagen represses cyclin E1 via ß1 integrin in invasive breast cancer cells. Breast Cancer Res Treat 2011; 127: 397-406.
85. Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 2013; 139: 853-860.